OINDPnews


H&T Presspart banner

Business

COPD Foundation partners with ENA Respiratory on development of pan-antiviral nasal spray

The COPD Foundation has partnered with ENA Respiratory for development of ENA's INNA-051 pegylated TLR2/6 agonist pan-antiviral nasal spray in patients with chronic lung disease, the company said. In June 2021, ENA Respiratory announced that it had raised A$32 million for development of INNA-051 and planned a Phase 1 trial. According to ENA, the Phase 1 study of … [Read more...] about COPD Foundation partners with ENA Respiratory on development of pan-antiviral nasal spray

Ferrer gets distribution rights to Tyvaso inhalation solution in much of the world

Ferrer has acquired the rights to distribute United Therapeutics' Tyvaso treprostinil inhalation solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) outside of the US, Canada, Israel, Japan, and China. Terms of the deal were not disclosed. Tyvaso inhalation solution is currently approved for the treatment of … [Read more...] about Ferrer gets distribution rights to Tyvaso inhalation solution in much of the world

AstraZeneca partners with Honeywell on development of HFO-1234ze MDIs

AstraZeneca has announced a partnership with Honeywell for development of lower global warming potential MDIs using HFO-1234ze as a propellant. The company said that Breztri budesonide/ glycopyrronium/ formoterol fumarate is the first product it plans to convert to HFO-1234ze and that a Phase 1 trial of an HFO 1234ze formulation of budesonide/ glycopyrronium/ … [Read more...] about AstraZeneca partners with Honeywell on development of HFO-1234ze MDIs

Glenmark acquires rights to market Pulmicort Respules in Columbia

Glenmark Pharmaceuticals said that its subsidiary Glenmark Pharmaceuticals Columbia has acquired exclusive rights to commercialize AstraZeneca's Pulmicort Respules budesonide inhalation suspension for the treatment of asthma in Columbia. AstraZeneca will manufacture the inhalation suspension and supply the product to Glenmark. Glenmark Executive VP and Global Head, … [Read more...] about Glenmark acquires rights to market Pulmicort Respules in Columbia

Inhaled NO developer Third Pole closes $25 million financing round

Third Pole Therapeutics announced that it has raised an additional $25 million in a financing round led by existing investors for continued development of its tankless inhaled nitric oxide (iNO) systems. The company also said that its eNOcare iNO platform is almost ready to launch and that clinical trials of its eNOfit wearable iNO device are expected to begin by the … [Read more...] about Inhaled NO developer Third Pole closes $25 million financing round

Ethris raises $26.3 million for development of inhaled mRNA therapies

Ethris GmbH said that it has closed a $26.3 million Series B financing round led by Laureus Capital, with proceeds earmarked for continued development of the company's ETH47 and ETH42 inhaled mRNA based therapies, which are currently in preclinical development. The company also said that Laureus Capital founder and CEO Christian Wawrzinek will become Managing … [Read more...] about Ethris raises $26.3 million for development of inhaled mRNA therapies

Gates Foundation awards $1.9 million grant to Aridis for development of inhaled mAbs

Aridis Pharmaceuticals announced that it has received an award of $1.9 million from the Bill & Melinda Gates Foundation to fund preclinical development of inhaled monoclonal antibodies against influenza and SARS-CoV-2. Aridis is developing both dry powder and liquid inhalation formulations in collaboration with Lumen Bioscience, the University of Alabama at … [Read more...] about Gates Foundation awards $1.9 million grant to Aridis for development of inhaled mAbs

Leyden Labs raises $140 million for development of intranasal vaccines

Intranasal vaccine developer Leyden Laboratories has closed a $140M Series B financing led by Casdin Capital and GV, the company said. Proceeds will go toward development of the company's pipeline, which includes its PanFlu intranasal mAb vaccine against both influenza A and B. Leyden Labs previously announced a €40 million Series A financing in March 2021. In … [Read more...] about Leyden Labs raises $140 million for development of intranasal vaccines

Opiant gets additional $2.2 million in BARDA funding for development of OPNT003 intranasal nalmefene

According to Opiant Pharmaceuticals, the company's contract with the Biomedical Advanced Research and Development Authority (BARDA) has been amended to provide an additional $2.2 million to support activities related to a 505(b)(2) NDA submission for OPNT003 nalmefene nasal spray for the treatment of opioid overdose. In July 2021, Opiant announced positive results … [Read more...] about Opiant gets additional $2.2 million in BARDA funding for development of OPNT003 intranasal nalmefene